24/7 Wall Street
02 Jul 2026, 13:33 UTC · 1h ago
Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime' to Make Money
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
24/7 Wall Street
02 Jul 2026, 13:33 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Voyager Therapeutics expects to begin first-in-human dosing for its Alzheimer's drug VY1706 in the second half of 2026. — Clinical trial initiation is a primary catalyst for biotech valuations and could validate the 'Year of Tau' thesis.
+0.60Voyager Therapeutics authorized 240 million shares of common stock as of June 9, 2026. — A large share authorization significantly increases the risk of equity dilution for current shareholders.
-0.50Voyager's Q1 FY26 revenue of $2.59 million missed the $8.79 million consensus by over 70%. — A substantial revenue miss indicates a sharp decline in collaboration funding as research phases mature.
-0.40Continue reading
6 related stories
Top 1 mover · tap to explore
The company reports cash on hand of $171.66 million, providing an operational runway into 2028. — Sufficient cash runway reduces the immediate necessity for emergency financing or bankruptcy risk.
CFO Nathan Jorgensen resigned in May 2026. — Executive turnover in the finance department creates operational uncertainty and potential instability.
-0.20Which stocks this story touches
Oppenheimer initiated coverage with an Outperform rating and a $10 price target.
Despite analyst buy ratings and upcoming trials, the company has significant losses, a CFO resignation, and a long-term stock price decline.
Collaboration revenue with Voyager Therapeutics has dropped as deals matured.
Mentioned only as a historical reference for an analyst's accuracy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
GlobeNewsWire
7h ago
